NATIONAL D I ABET ES DEI TACUON PROGRA M Changing the way diabetes is treated.

Slides:



Advertisements
Similar presentations
Today’s Agenda Discuss the prevention and management of cardiovascular complications of diabetes Mention the other complications along with prevention.
Advertisements

Robert M. Guthrie, MD Professor of Emergency Medicine
NCEP ATP IV GuidelineS: 2013 Update
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Benefits of intensive multiple risk factor intervention.
 Currently 150 Million people worldwide suffering from diabetes and that number may double by the year  The prevalence of type 2 diabetes is dramatically.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Overview of the CVD Risk Reduction Demonstration Project Kelly Acton, MD, MPH, FACP IHS Division of Diabetes Treatment & Prevention.
Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Managing Diabetes Medications. Topics What medications are available to –Manage diabetes? –Lower blood pressure? –Improve cholesterol? How can you keep.
Managing Diabetes What Is Diabetes? and Diabetes ABCs.
Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
DIABETES With All My Heart Presented by: Regina Weitzman, MD.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
... a KAISER PERMANENTE Innovation IndiGO: Tailoring Guidelines to Individuals David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes.
1. Public Awareness Survey on 2,000 People with Diabetes (Fall 2001)  Findings: –68% do not consider cardiovascular disease to be complication of diabetes.
RISK FACTOR FOR CORONARY ARTERY DISEASE
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Quality improvement in non glycaemic targets in diabetic patients at Central Australian Aboriginal Congress John Boffa Public Health Medical Officer.
IMPROVING DIABETES CARE FOR ADULTS: A Population-Based Approach Patrick J. O’Connor, MD, MPH Senior Clinical Investigator HealthPartners Research Foundation.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
An Innovative Approach to Managing Diabetes in a Large Public Health System Donna J. Calvin, PhD, FNP-BC, CNN Post Doctoral Research Associate University.
Hypertension & diabetes: new guidelines Janice Douglas, MD Case Western University Cleveland, OH George L Bakris, MD Director of the Hypertension/Clinical.
Studying mortality trends: The IMPACT CHD Policy Model
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Elizabeth Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Director, Clinical Research Center Associate Dean of Clinical Research.
3 rd Annual Right Care Summit October 1 st, 2010 Stephen M. Shortell Ph.D., M.P.H. Dean, University of California, Berkeley, School of Public Health.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Clinical Health Indicator Improvements and Hospital Usage Report Health Integration Project December 2013 Matthew Rich Matthew Rich – Health Integration.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
February 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
GO! Diabetes Train the Trainer Program. Practice Performance and Improvement.
Familial Hypercholesterolemia Foundation Patient Engagement and the Assessment of Value Cat Davis Ahmed Director of Outreach.
Management of Hypertension according to JNC 7
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Redefining Quality Care in T2DM Patients with CV Disease
Objective Use a well validated large-scale computer simulation model to compare the clinical and cost effectiveness of several screening strategies to.
ACCORD Design and Baseline Characteristics
Vanguard Phase Results for the Blood Pressure Component
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Diabetes Health Status Report
Diabetic Dyslipidemia in Practice
Heart Health & Diabetes
Macrovascular Complications Microvascular Complications
Cardiovascular Disease (CVD) in Texas
Getting the Best Care for Your Diabetes
These slides highlight a cardiology grand rounds and cardiology research rounds presented by William James Howard, MD at St. Michael’s Hospital, in Toronto,
Section I: RAS manipulation C. Update on clinical trials in CAD
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.
Section 7: Aggressive vs moderate approach to lipid lowering
Evaluating the cost-effectiveness of interventions with an impact on ageing P. Breeze, P. Thokala, L. Lafortune, C. Brayne, A. Brennan 07/12/2018.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
The Heart Truth Delaware Background
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Prepared by :Dr. Latifa Mari’e
Section 6: Update on lipid treatment guidelines
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

NATIONAL D I ABET ES DEI TACUON PROGRA M Changing the way diabetes is treated.

Purpose of the Session Update on NDEP activities Review accomplishments of race/ethnic work groups Plans for new comprehensive care campaign Obtain input for future planning Changing the way diabetes is treated

How is science driving NDEP activities? DCCT: Metabolic control matters. Changing the way diabetes is treated

How has the science evolved? UKPDS: Blood pressure control matters 4S and West of Scotland: cholesterol control makes a difference Meta-analysis of aspirin data: aspirin therapy works for PWD Changing the way diabetes is treated

How have practice guidelines changed? JNC VI ATP III ADA Clinical Guidelines Changing the way diabetes is treated

We are changing the way diabetes is treated. DQIP AMA, JCAHO and NCQA AHA New therapies Major education campaigns Changing the way diabetes is treated

NDEP Accomplishments Control Your Diabetes. For Life. campaign Educational materials Clinical tools Key partners working together Changing the way diabetes is treated

We still need to bridge the gap. Current CareDesired Care

5 Components of the NDEP Awareness Campaigns Special Populations Partnership Network Community Interventions Health Systems

Changing the Way Diabetes Is Treated

Comprehensive Diabetes Control Changing the way diabetes is treated

Risk Factors for Complications of Type 2 Diabetes PercentPercent NHANES III, Hba1c Albumin- Hyper LDL HDL Trigly- BMI Cigarette >7% uria tension> smoking >200

The Good News: People with diabetes can take steps to significantly reduce their risk of heart disease Changing the way diabetes is treated

The ABCs of Diabetes Control A = A1C B = Blood pressure C = Cholesterol

Changing the way diabetes is treated The Science Behind the ABCs of Diabetes Control

Changing the way diabetes is treated A1C DCCT : Intensive blood glucose therapy reduced risk of microvascular complications EDIC : Microvascular benefits endure EDIC : Intensive therapy reduced risk of atherosclerosis

Changing the way diabetes is treated Blood Pressure UKPDS 10-point reduction in systolic and 5-point reduction in diastolic blood pressure 21% decrease in heart attack risk 44% decrease in stroke risk

Changing the way diabetes is treated Blood Pressure Hypertension Optimal Treatment Study (HOT) Three diastolic goals: 80, 85, and 90 51% reduction in CV events at diastolic pressure of 80

Changing the way diabetes is treated Controlling Blood Pressure in People with Diabetes ABCD and HOPE: effectiveness of ACE inhibitors HOPE: % reduction in risk of heart attack, stroke, or CV death UKPDS: beta blockers and ACE inhibitors worked equally well

Changing the way diabetes is treated Controlling Cholesterol in People with Diabetes CARE: 25% reduction in heart attacks or CV deaths using statin therapy 4S significantly reduced CHD incidence with simvastatin NCEP: recommends LDL- cholesterol < 100 for people with diabetes

The Bottom Line: Aggressive control of blood glucose, blood pressure, and cholesterol can make a big difference in outcomes for people with diabetes. Changing the way diabetes is treated

Be Smart About Your Heart Campaign Logo Insert “Be Smart” campaign logo

Diabetes is a key risk factor for CVD Rigorous control of blood glucose, blood pressure, and cholesterol helps prevent CVD and other diabetes complications. Move more, eat better, and take medications as prescribed, to feel better and enjoy a better quality of life. Campaign Messages Changing the way diabetes is treated

Campaign Messages What are my A1C, blood pressure and cholesterol numbers? What are my treatment goals? What do I need to do to reach my goals? Changing the way diabetes is treated

Campaign Components Educational materials Mass media messages Special populations tailored messages Clinical tools Participation of NDEP partner organizations

How can you help? Promote the ABCs of Diabetes to your patients and your colleagues Reinforce the physical activity and healthy eating messages Changing the way diabetes is treated

Find out more: Call to order materials Call for Hispanic campaign materials Call to speak with a diabetes information specialist Visit the NDEP Web Sites – – Changing the way diabetes is treated